A systematic review: the current status of carbapenem resistance in East Africa

BMC Research Notes
Kenneth SsekatawaFrancis Ejobi

Abstract

In this systematic review, we present the molecular epidemiology and knowledge gaps of the carbapenem resistance in East Africa as well as the future probable research interventions that can be used to address the emergence of carbapenem resistance in the region. The 17 articles which presented concrete information about the prevalence of carbapenem resistance in East Africa were reviewed. Tanzania exhibited the highest level of carbapenem resistance at 35% while DRC had the lowest level at 0.96%. Uganda was the only country with studies documenting CR obtained amongst hospital environment isolates with incidence ranging from 21% in Pseudomonas aeruginosa to 55% in Acinetobacter baumannii. Carbapenem resistance was more exhibited in A. baumannii (23%), followed by P. aeruginosa (17%), Klebsiella pneumoniae (15%), Proteus mirabilis (14%) and Escherichia coli (12%) mainly isolated from respiratory tract, blood, urine and wound/pus. The regional genetic determinants of carbapenem resistance detected were blaIMP, blaVIM-1 blaSPM-l, blaNDM-1, blaOXA-23 blaOXA-24, blaOXA-58 and blaKPC.

References

May 15, 1991·The Biochemical Journal·R P AmblerS G Waley
Jul 8, 2005·Journal of Clinical Microbiology·Johann D D PitoutDeirdre L Church
Jul 17, 2007·Clinical Microbiology Reviews·Anne Marie Queenan, Karen Bush
Aug 30, 2008·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J D D PitoutL Poirel
Sep 2, 2009·Antimicrobial Agents and Chemotherapy·Laurent PoirelPatrice Nordmann
Dec 1, 2010·Antimicrobial Agents and Chemotherapy·Laurent PoirelPatrice Nordmann
Jun 11, 2011·The Lancet Infectious Diseases·Daniel J MorganScott Weisenberg
Nov 15, 2011·Trends in Microbiology·Patrice NordmannDavid M Livermore
Apr 7, 2012·Trends in Molecular Medicine·Patrice NordmannLaurent Poirel
Nov 2, 2012·Journal of Clinical Microbiology·A LernerY Carmeli
Mar 19, 2013·Frontiers in Microbiology·Gopi Patel, Robert A Bonomo
Nov 2, 2013·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Gunturu RevathiLi-Yueh Huang
Sep 28, 2014·The Journal of Antimicrobial Chemotherapy·Rendani I ManenzheMamadou Kaba
Apr 17, 2015·Infection and Drug Resistance·Vangelis Economou, Panagiota Gousia
Nov 26, 2015·British Microbiology Research Journal·Lucas M AmpaireJoel Bazira
Feb 10, 2017·Infection and Drug Resistance·Melese Hailu LegeseDaniel Asrat
Aug 10, 2017·International Journal of Medical Microbiology : IJMM·Sonal P HensonSusan C Morpeth
Sep 8, 2017·African Journal of Laboratory Medicine·Lucas AmpaireYap Boum

❮ Previous
Next ❯

Citations

Aug 23, 2020·International Journal of Molecular Sciences·Chris R TaittGary J Vora
Oct 13, 2020·Current Opinion in Infectious Diseases·Jonathan BroadShamez Ladhani

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
Whole Genome sequencing

Software Mentioned

PCR Phoenix Automated Microbiology System
XLSTAT

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.